IP Verse

Recombinant Adeno-Associated Virus Particle Purification Comprising An Affinity Purification Step - EP3256574

The patent EP3256574 was granted to Association Franaise Contre LES Myopathies on Nov 25, 2020. The application was originally filed on Feb 9, 2016 under application number EP16704576A. The patent is currently recorded with a legal status of "Revoked".

EP3256574

ASSOCIATION FRANAISE CONTRE LES MYOPATHIES
Application Number
EP16704576A
Filing Date
Feb 9, 2016
Status
Revoked
Mar 21, 2025
Grant Date
Nov 25, 2020
External Links
Slate, Register, Google Patents

Patent Summary

Patent Family

Patent Family

Patent Oppositions (8)

Patent oppositions filed by competitors challenge the validity of a granted patent. These oppositions are typically based on claims of prior art, lack of novelty, or non-obviousness. They are a key part of the process for determining a patent's strength and enforceability.

CompanyOpposition DateRepresentativeOpposition Status

Get instant alerts for new oppositions and patent status changes

EUROPEAN OPPOSITIONSAug 25, 2021SIMMONS & SIMMONSADMISSIBLE
J A KEMPAug 25, 2021J A KEMPADMISSIBLE
JAMES POOLEAug 25, 2021CARPMAELS & RANSFORDADMISSIBLE
JG OPPOSITIONSAug 25, 2021GREGSONADMISSIBLE
KONIG SZYNKA TILMANN VON RENESSEAug 25, 2021KONIG SZYNKA TILMANN VON RENESSE DUSSELDORFADMISSIBLE
KONIG SZYNKA TILMANN VON RENESSEAug 25, 2021KONIG SZYNKA TILMANN VON RENESSE PATENTANWALTE PARTNERSCHAFT MBB DUSSELDORFADMISSIBLE
DEFINITIONAug 24, 2021DEFINITIONADMISSIBLE
OETKEAug 24, 2021WALLINGER RICKER SCHLOTTER TOSTMANNADMISSIBLE

Patent Citations (33) New

Patent citations refer to prior patents cited during different phases such as opposition or international search.

Citation PhasePublication NumberPublication Link
DESCRIPTIONUS5139941
DESCRIPTIONUS5173414
DESCRIPTIONUS6376237
DESCRIPTIONWO03097797
DESCRIPTIONWO2011094198
DESCRIPTIONWO9201070
DESCRIPTIONWO9303769
INTERNATIONAL-SEARCH-REPORTWO2010148143
INTERNATIONAL-SEARCH-REPORTWO2011094198
OPPOSITIONEP15305188
OPPOSITIONEP2492347
OPPOSITIONUS2004106184
OPPOSITIONUS2004229335
OPPOSITIONUS2006088869
OPPOSITIONUS2007254352
OPPOSITIONUS2009325284
OPPOSITIONUS6566118
OPPOSITIONUS6660514
OPPOSITIONUS6841357
OPPOSITIONUS6989264
OPPOSITIONUS7625570
OPPOSITIONUS7851196
OPPOSITIONWO0148155
OPPOSITIONWO0212455
OPPOSITIONWO03039459
OPPOSITIONWO03097797
OPPOSITIONWO2005118792
OPPOSITIONWO2010148143
OPPOSITIONWO2011094198
OPPOSITIONWO2013036118
OPPOSITIONWO2016128408
OPPOSITIONWO9708298
OPPOSITIONWO9822588

Non-Patent Literature (NPL) Citations (116) New

NPL citations refer to non-patent references such as research papers, articles, or other publications cited during examination or opposition phases.

Citation PhaseReference TextLink
DESCRIPTION- BERNS; BOHENZKY, Advances in Virus Research, ACADEMIC PRESS, INC., (1987), vol. 32, pages 243 - 307-
DESCRIPTION- CARTER, B. J., CURRENT OPINION IN BIOTECHNOLOGY, (1992), vol. 3, pages 533 - 539-
DESCRIPTION- CHU ET AL., GENE, (1981), vol. 13, page 197-
DESCRIPTION- COLE ET AL., MOL CELL BIOL., (1984), vol. 62, pages 109 - 120-
DESCRIPTION- COTE ET AL., PROC.NATL.ACAD.SCI., (1983), vol. 80, pages 2026 - 2030-
DESCRIPTION- GRAHAM ET AL., VIROLOGY, (1973), vol. 52, page 456-
DESCRIPTION- HEUKESHOVEN, J.; DERNICK, R., ELECTROPHORESIS, (1985), vol. 6, pages 103 - 112-
DESCRIPTION- KOHLER ET AL., NATURE, (1975), vol. 256, pages 495 - 497-
DESCRIPTION- KOTIN, R. M., HUMAN GENE THERAPY, (1994), vol. 5, pages 793 - 801-
DESCRIPTION- KOZBOR, J. IMMUNOL. METHODS, (1985), vol. 81, pages 31 - 42-
DESCRIPTION- LEBKOWSKI ET AL., MOLEC. CELL. BIOL., (1988), vol. 8, pages 3988 - 3996-
DESCRIPTION- MCCARTY ET AL., J. VIROL., (1991), vol. 65, pages 2936 - 2945-
DESCRIPTION- MUZYCZKA, N., CURRENT TOPICS IN MICROBIOL, AND IMMUNOL., (1992), vol. 158, pages 97 - 129-
DESCRIPTION- PETIT ET AL., "Restoration of vision in the pde6,8-deficient Dog, ? Large Animal Model of Rod-cone Dystrophy", MOLECULAR THERAPY, (2012), vol. 20, no. LL, pages 2019 - 2030-
DESCRIPTION- PULICHERLA ET AL., GEN THER, (2011), vol. 18, no. 10, pages 1020 - 1024-
DESCRIPTION- PULICHERLA ET AL., "Peptide affinity reagents for AAV capsid recognition and purification", GENE THER., (2011), vol. 18, no. 10, pages 1020 - 1024-
DESCRIPTION- SAMUL-SKI ET AL., J. VIROL., (1989), vol. 63, pages 3822 - 3828-
DESCRIPTION- LE MEUR ET AL., "Restoration of vision in RPE65-deficient Briard dogs using an AAV serotype 4 vector that specifically targets the retinal pigmented epithelium", GENE THERAPY, (2007), vol. 14, doi:doi:10.1038/sj.gt.3302861, pages 292 - 303, XP002493281
DESCRIPTION- MOSER; HAGE, "Immunoaffinity chromatography : an introduction to applications and recent developments", BIOANALYSIS, (2010), vol. 2, no. 4, doi:doi:10.4155/bio.10.12, pages 769 - 790, XP009174086
EXAMINATION- Commission Regulation (EU) 2017/999 of 13 June 2017-
EXAMINATION- Millistak+ HC Pod filter data sheet-
EXAMINATION- Opticap XL10 Express SHC filter data sheet-
EXAMINATION- Polygard CN data sheet-
EXAMINATION- Polysep II data sheet-
OPPOSITION- Alton Eric, "Progress and prospects: gene therapy clinical trials (part 1)", Gene Therapy, (20070101), vol. 14, no. 20, pages 1439 - 1447, XP055850573-
OPPOSITION- Anonymous, "Microfiltration Membranes for the Laboratory", MILLIPORE, (20090000), pages 1 - 3, XP055840177-
OPPOSITION- AYUSO, E., "Manufacturing of recombinant adeno-associated viral vectors: new technologies are welcome", Molecular Therapy - Methods 6t Clinical Development, (20160000), vol. 3, no. 15049, pages 1 - 3, XP055840183-
OPPOSITION- Binny Christopher J., Nathwani Amit, "Vector systems for prenatal gene therapy: principles of adeno-associated virus vector design and production", Prenatal Gene Therapy, (20120101), vol. 891, pages 109 - 131, XP055850570-
OPPOSITION- BRUMENT, N. et al., "A Versatile and Scalable Two-Step lon-Excahnge Chromatography Process for the Purification of Recombinant Adeno-associated virus Serotypes-2 and -5", Molecular Therapy, (20021100), vol. 6, no. 5, pages 678 - 686, XP055840268-
OPPOSITION- CECCHINI S. et al., "Reproducible High Yields of Recombinant Adeno-Associated Virus Produced Using Invertebrate Cells in 0.02- to 200-Liter Cultures", Human Gene Therapy, (20110000), vol. 22, pages 1021 - 1030, XP055840190-
OPPOSITION- Cecchini S., Et Al., "Reproducible High Yields of Recombinant Adeno-Associated Virus Produced Using Invertebrate Cells in 0.02- to 200-Liter Cultures", Human Gene Therapy, (20110101), pages 1021 - 1030, XP055840190-
OPPOSITION- CECCHINI, S. et al., "Reproducible high yields of recombinant adeno-associated virus produced using invertebrate cells in 0.02-to 200-liter cultures", Human Gene Therapy, (20110800), vol. 22, no. 8, pages 1021 - 1030, XP055840190-
OPPOSITION- "Chapter 24. Recombinant adeno-associated viral vectors", DE BACKER, M. W. et al., Neuropeptides: Methods and Protocols, Methods in Molecular Biology, Springer, (20110000), vol. 789, pages 357 - 376, XP055840296-
OPPOSITION- Data sheet Pall Profile® Star, (20140000), XP055850589-
OPPOSITION- Data sheet Pall Ultipleat Profile-
OPPOSITION- D. GRIMM ET AL., "Novel tools for production and purification of recombinant adenoassociated virus vectors", HUMAN GENE THERAPY, Mary Ann Liebert, Inc. Publishers, GB, GB, (19981210), vol. 09, no. 18, ISSN 1043-0342, pages 2745 - 2760, XP002093963-
OPPOSITION- Doria Monica, Et Al, "AAV2/8 Vectors Purified from Culture Medium with a Simple and Rapid Protocol Transduce Murine Liver, Muscle, and Retina Efficiently", Human Gene Therapy Methods, (20131201), vol. 24, pages 392 - 398, XP055850454-
OPPOSITION- Ge Healthcare, "AVB Sepharoseâ„¢ High Performance", GE Healthcare - Data sheet, (20161201), pages 1 - 6, GE Healthcare - Data sheet, (20210913), XP055840285-
OPPOSITION- GE Healthcare, "AVB Sepharoseâ„¢ High Performance", GE Healthcare - Data sheet, (201612), pages 1 - 6, XP055840285-
OPPOSITION- GE Healthcare Ion Exchange Chromatography Principles and Methods, (20040400), XP055601234-
OPPOSITION- Hermens Wim, "A modular and disposable manufacturing platform for adeno-associated viral vectors", Presentation made by Amsterdam Molecular Therapeutics (AMT) at teh American Society Gene Therapy (ASGT). 11th Annual Meeting Boston USA, (20080528), pages 1 - 34, Presentation made by Amsterdam Molecular Therapeutics (AMT) at teh American Society Gene Therapy (ASGT). 11th Annual Meeting Boston USA, (20211012), XP055850463-
OPPOSITION- Leadbetter J, "Methods in Enzymology. Excerpt", Environmental Microbiology, (20050101), vol. 397, page 277, XP055850447-
OPPOSITION- Le Meur G, "Efficacy and safety of gene therapy with AAV4 in childhood blindness due to rpe65 mutations. Abstract", Acta Opthalmologica, (20120806), vol. 90, no. s249, pages 1 - 2, XP055850451-
OPPOSITION- Mietzsch Mario, "Adeno-Associated Virus Vectors for Gene Therapy: From Scalable Production Systems via Serotype-Specific Glycan Interaction Patterns to Gene Transfer Applications", PhD thesis, (20140801), PhD thesis, URL: https://refubium.fu-berlin.de/bitstream/handle/fub188/6047/Mietzsch_Mario.diss.pdf?sequence=1&isAllowed=y, (20211208), XP055870385-
OPPOSITION- Oranje Paul P. A. , Verheesen Peter, Verbart Dennis, Mijnsbergen Yvonne, Haard Hans J W, Hermans Pim, Ten Haaft Mark R, Twisk Jaap, Dijkhuizen Paul A, Hermens Wim T J M C, Meulenberg Janneke J M, "Isolation of an adeno-associated virus (AAV)-specific camelid-derived single chain antibody fragment: a novel tool for purification of AAV vectors of different serotypes", Molecular Therapy, Elsevier Inc., US, US , (20040501), vol. 9, doi:10.1016/j.ymthe.2004.06.344, ISSN 1525-0016, page 162, XP004634789-
OPPOSITION- Samulski R. Jude, Muzyczka Nicholas, "AAV-mediated gene therapy for research and therapeutic purposes", Annual review of virology, (20141101), vol. 1, pages 427 - 451, XP055850562-
OPPOSITION- SEGURA, M. M. et al., "Overview of current scalable methods for purification of viral vectors", Viral Vectors for Gene Therapy, (20110400), pages 89 - 116, XP009151623-
OPPOSITION- Shukla A A, Et Al, "Process Scale Bioseparation For The Biopharmaceutical Industry. Chapter 1", CRC Press Taylor & Francis, (20070101), pages 1 - 23, XP055850457-
OPPOSITION- SMITH, R. H. et al., "Chromatography-based purification of adeno-assocaited virus", SMITH, R. H. et al., J. M. Le Doux, Methods in Molecular Biology, Humana Press, (20080000), pages 37 - 54, XP055841150-
OPPOSITION- SMITH, R. H. et al., "Chromatography-based purification of adeno-associated virus", Gene Therapy Protocols, (20080000), pages 37 - 54, XP055841150-
OPPOSITION- WANG, L. et al., "715. A Rapid, Scalable, Two-step Column Chromatography Purification of rAAV Vectors", Molecular Therapeutics, (20090000), vol. 17, page S273, XP055840276-
OPPOSITION- WANG L. et al., "715. A Rapid, Scalable, Two-Step Column Chromatography Purification of rAAV Vectors", Molecular Therapy, (20090500), vol. 17, no. 1, page 1, XP055840188-
OPPOSITION- WANG, L. et al., "A rapid, scalable, two-step column chromatography purification of rAAV vectors", Molecular Therapy, (20090500), vol. 17, no. S723, page 715, XP055840276-
OPPOSITION- WANG, L. et al., "Two-Step Chromatogprahy Purification of rAAV1 vectors produced by suspension BHK cells rHSV co-infection", American Society of Gene Therapy 12th Annual Meeting, (20090501), vol. 17, no. Supp 1, XP055841171-
OPPOSITION- WEITZMAN, M. D. et al., "Chapter 1 Adeno-Associated Virus Biology", WEITZMAN, M. D. et al., Richard O. Snyder, Philippe Moullier, Adeno-Associated Virus: Methods and Protocols, Springer, (20110000), pages 1 - 23, XP055841181-
OPPOSITION- YE et al., "Herpes Simplex Virus Clearance During Purification of a Recombinant Adeno-Associated Virus Serotype 1 Vector", HUMAN GENE THERAPY CLINICAL DEVELOPMENT, (20141200), vol. 25, pages 212 - 217, XP055840194-
OPPOSITION- YE, G. et al., "Herpes Simplex Virus Clearance During Purification of a Recombinant Adeno-Associated Virus Serotype 1 Vector", Human Gene Therapy Clinical Development, (20140000), vol. 25, pages 212 - 217, XP055840194-
OPPOSITION- Ye G., Et Al., "Herpes Simplex Virus Clearance During Purification of a Recombinant Adeno-Associated Virus Serotype 1 Vector", Human Gene Therapy Clinical Development, (20140101), vol. 25, pages 212 - 217, XP055840194-
OPPOSITION- YE, G. J. et al., "Herpes simplex virus clearance during purification of a recombinant adeno-associated virus serotype 1 vecto r", Human Gene Therapy Clinical Development, (20141200), vol. 25, no. 4, pages 212 - 217, XP055840194-
OPPOSITION- WANG, L. et al., "Production and purification of recombinant adeno-associated vectors", Adeno-Associated Virus, (20110900), doi:10.1007/978-1-61779-370-7_16, pages 361 - 404, XP009155688
OPPOSITION- WANG, L. et al., "Production and Purification of Recombinant Adeno-Associated Vectors (Chapter 16", Adeno-Associated Virus: Methods and Protocols, (20110000), doi:10.1007/978-1-61779-370-7_16, pages 361 - 404, XP009155688
OPPOSITION- WANG L. et al., "Production and Purification of Recombinant Adeno-Associated Vectors", Methods in Molecular Biology, vol. 807, no. Chapter 16, doi:10.1007/978-1-61779-370-7_16, pages 361 - 404, XP009155688
OPPOSITION- Wang Lijun; Blouin Véronique; Brument Nicole; Bello-Roufai Mahajoub; Francois Achille, "Production and purification of recombinant adeno-associated vectors.", Antibody-drug conjugates; IN: Methods in Molecular Biology; ISSN 1064-3745; Vol. 263, Humana Press, US, US , (20110101), vol. 807, doi:10.1007/978-1-61779-370-7_16, ISBN 978-1-62703-541-5, pages 361 - 404, XP009155688
OPPOSITION- QU, W. et al., "Calcium-ion- modulcated ceramic hydroxyapatite resin for the scalable purification of recombinant Adeno-Associated Virus serotype 9", Jouranl of Chromatography, (201505), vol. 990, pages 15 - 22, XP055840293
OPPOSITION- SMITH, R. H. et al., "Serum-free production and column purification of adeno-associated virus type 5", Journal of Viriological Methods, (20030000), doi:10.1016/j.jviromet.2003.09.002, pages 115 - 124, XP055316815
OPPOSITION- DAVIDOFF, A. M. et al., "Purification of recombinant adeno-associated virus type 8 vectors by ion exchange chromatography generates clinical grade vector stock", Journal of Virological Methods, (20040800), vol. 121, no. 2, doi:10.1016/j.jviromet.2004.07.001, pages 209 - 215, XP004572265
OPPOSITION- QU, G. et al., "Separation of adeno-associated virus type 2 empty particles from genome containing vectors by anion-exchange column chromatography", J ournal of Virological Methods, (20061200), vol. 140, no. 1-2, doi:10.1016/j.jviromet.2006.11.019, pages 183 - 192, XP005870426
OPPOSITION- OKSANEN, H. M. et al., "Monolithic ion exchange chromatographic methods for virus purification", Virology, (20121000), vol. 434, no. 2, doi:10.1016/j.virol.2012.09.019, pages 271 - 277, XP028960350
OPPOSITION- URABE M. et al., "Removal of Empty Capsids from Type 1 Adeno- Associated Virus Vector Stocks by Anion-Exchange Chromatography Potentiates Transgene Expression", Molecular Therapy, (20060213), vol. 13, no. 4, XP005358617
OPPOSITION- URABE, M. et al., "Removal of empty capsids from type 1 adeno-associated virus vector stocks by anion-exchange chromatography potentiates transgene expression", Molecular Therapy, (20060400), vol. 13, no. 4, doi:10.1016/j.ymthe.2005.11.024, pages 823 - 828, XP005358617
OPPOSITION- Urabe, M. Xin, K.Q. Obara, Y. Nakakura, T. Mizukami, H. Kume, A. Okuda, K. Ozawa, K., "Removal of Empty Capsids from Type 1 Adeno-Associated Virus Vector Stocks by Anion-Exchange Chromatography Potentiates Transgene Expression", Molecular Therapy, Elsevier Inc., US, US , (20060401), vol. 13, no. 4, doi:10.1016/j.ymthe.2005.11.024, ISSN 1525-0016, pages 823 - 828, XP005358617
OPPOSITION- Urabe, M. Xin, K.Q. Obara, Y. Nakakura, T. Mizukami, H. Kume, A. Okuda, K. Ozawa, K., "Removal of Empty Capsids from Type 1 Adeno-Associated Virus Vector Stocks by Anion-Exchange Chromatography Potentiates Transgene Expression", Molecular Therapy, Elsevier Inc., US, US, (20060401), vol. 13, no. 4, doi:10.1016/j.ymthe.2005.11.024, ISSN 1525-0016, pages 823 - 828, XP005358617
OPPOSITION- ZOLOTUKHIN, S. et al., "Production and purification of Serotype 1, 2, and 5 recombinant adeno-associated viral vector s", Methods, (20020000), doi:10.1016/S1046-2023(02)00220-7, pages 158 - 167, XP002256404
OPPOSITION- BRUMENT et al., "A Versatile and Scalable Two-Step Ion-Exchange Chromatography Process for the Purification of Recombinant Adeno-associated Virus Serotypes-2 and -5", MOLECULAR THERAPY, (20020000), vol. 6, no. 5, doi:10.1016/S1525-0016(02)90719-7, XP002969618
OPPOSITION- BRUMENT, N. et al., "A versatile and scalable two-step ion-exchange chromatography process for the purification of recombinant adeno-associated virus serotypes-2 and-5", Molecular Therapy, (20021100), vol. 6, no. 5, doi:10.1016/S1525-0016(02)90719-7, pages 678 - 686, XP002969618
OPPOSITION- KNOP, D. R. et al., "Bioreactor Production of Recombinant Herpes Simplex Virus Vectors", Biotechnology Progress, (20070000), doi:10.1021/bp060373p, pages 715 - 721, XP055041050
OPPOSITION- W Kang, L Wang, H Harrell, J Liu, D L Thomas, T L Mayfield, M M Scotti, G J Ye, G Veres, D R Knop, "An efficient rHSV-based complementation system for the production of multiple rAAV vector serotypes", Gene Therapy, Nature Publishing Group, London, GB, GB, (20090201), vol. 16, no. 2, doi:10.1038/gt.2008.158, ISSN 0969-7128, pages 229 - 239, XP055731610
OPPOSITION- CECCHINI, S. et al., "Toward exascale production of recombinant adeno-associated virus for gene transfer applications", Gene Therapy, (20080400), vol. 15, no. 11, doi:10.1038/gt.2008.61, pages 823 - 830, XP002679918
OPPOSITION- CECCHINI S, NEGRETE A, KOTIN R M, "Toward exascale production of recombinant adeno-associated virus for gene transfer applications", Gene Therapy, Nature Publishing Group, London, GB, GB , (20080601), vol. 15, no. 11, doi:10.1038/gt.2008.61, ISSN 0969-7128, pages 823 - 830, XP002679918
OPPOSITION- WRIGHT, J. F., "Manufacturing and characterizing AAV-based vectors for use in clinical studies", Gene Therapy, (20080400), vol. 15, no. 11, doi:10.1038/gt.2008.65, pages 840 - 848, XP055182359
OPPOSITION- YE, G. J. et al., "Clearance and characterization of residual HSV DNA in recombinant adeno-associated virus produced by an HSV complementation system", Gene Therapy, (20100700), vol. 18, no. 2, doi:10.1038/gt.2010.102, pages 135 - 144, XP055182372
OPPOSITION- YE, G.-J. et al., "Clearance and characterization of residual HSV DNA in recombinant adeno-associated virus produced by an HSV complementation system", Gene Therapy, (20110000), doi:10.1038/gt.2010.102, pages 135 - 144, XP055182372
OPPOSITION- N Pulicherla, A Asokan, "Peptide affinity reagents for AAV capsid recognition and purification", Gene Therapy, Nature Publishing Group, London, GB, GB , (20111001), vol. 18, no. 10, doi:10.1038/gt.2011.46, ISSN 0969-7128, pages 1020 - 1024, XP055766382
OPPOSITION- PULICHERLA, N. et al., "Peptide affinity reagents for AAV capsid recognition and purification", Gene Therapy, (20110000), doi:10.1038/gt.2011.46, pages 1020 - 1024, XP055766382
OPPOSITION- SMITH, R. H. et al., "A simplified baculovirus-AAV expression vector system coupled with one- step affinity purification yields high-titer rAAV stocks from insect cells", Molecular Therapy, (20090000), vol. 17, no. 11, doi:10.1038/MT.2009.128, pages 1888 - 1896, XP002667812
OPPOSITION- SMITH, R. H. et al., "A Simplified Baculovirus-AAV Expression Vector System Coupled With One-step Affinity Purification Yields High- titer rAAV Stocks From Insect Cells", The American Society of Gene & Cell Therapy, (20090000), doi:10.1038/MT.2009.128, pages 1888 - 1896, XP002667812
OPPOSITION- CLEMENT, N. et al., "Manufacturing of recombinant adeno-associated viral vectors for clinical trials", Molecular Therapy-Methods & Clinical Development, (20160100), vol. 3, doi:10.1038/mtm.2016.2, page 16002, XP055387003
OPPOSITION- Donna J Palmer, Et Al., "Helper virus-mediated downregulation of transgene expression permits production of recalcitrant helper-dependent adenoviral vector", Molecular therapy- methods & clinical development, Nature Publishing Group, GB, GB, (20160608), vol. 3, doi:10.1038/mtm.2016.39, ISSN 2329-0501, XP055547362
OPPOSITION- MORENWEISER, R., "Downstream processing of viral vectors and vaccines", Gene Therapy, (20051000), vol. 12, no. 1, doi:10.1038/sj.gt.3302624, pages S103 - S110, XP002462513
OPPOSITION- LE MEUR et al., "Restoration of vision in RPE65-deficien Briard dogs using an AAV serotype 4 vector that specifically targets the retinal pigmented epithelium", Gene Therapy, (20070000), vol. 14, doi:10.1038/sj.gt.3302861, pages 292 - 303, XP002493281
OPPOSITION- LE MEUR, G. et al., "Restoration of vision in RPE65-deficient Briard dogs using an AAV serotype 4 vector that specifically targets the retinal pigmented epithelium", Gene Therapy, (20061000), vol. 14, no. 4, doi:10.1038/sj.gt.3302861, pages 292 - 303, XP002493281
OPPOSITION- MEUR G et al., "Restoration of vision in RPE65-deficient Briard dogs using an AAV serotype 4 vector that specifically targets the retinal pigmented epithelium", Gene Therapy, (20070000), vol. 14, doi:10.1038/sj.gt.3302861, pages 292 - 303, XP002493281
OPPOSITION- BAINBRIDGE et al., "Effect of Gene Therapy on Visual Function in Leber's Congenital Amaurosis", N Engl J Med, (20080522), vol. 358, doi:10.1056/NEJMoa0802268, pages 2231 - 9, XP002718542
OPPOSITION- KALUDOV N, HANDELMAN B, CHIORINI J A, "Scalable purification of adeno-associated virus type 2, 4, or 5 using ion-exchange chromatography", HUMAN GENE THERAPY, Mary Ann Liebert, Inc. Publishers, GB, GB , (20020701), vol. 13, no. 10, doi:10.1089/104303402320139014, ISSN 1043-0342, pages 1235 - 1243, XP002382732
OPPOSITION- URABE, M. et al., "Insect cells as a factory to produce adeno-associated virus type 2 vectors", Human Gene Therapy, (20021100), vol. 13, no. 16, doi:10.1089/10430340260355347, pages 1935 - 1943, XP002394454
OPPOSITION- LOCK, M. et al., "Analysis of Particle Content of Recombinant Adeno-Associated Virus Serotype 8 Vectors by Ion-Exchange Chromatography", Human Gene Therapy Methods, (20120000), doi:10.1089/hgtb.2011.217, pages 56 - 64, XP055349796
OPPOSITION- LOCK M. et al., "Analysis of Particle Content of Recombinant Adeno- Associated Virus Serotype 8 Vectors by lon- Exchange Chromatography", Human Gene Therapy Methods, (20120200), XP055349796
OPPOSITION- Martin Lock, Alvira Mauricio R., Wilson James M., "Analysis of Particle Content of Recombinant Adeno-Associated Virus Serotype 8 Vectors by Ion-Exchange Chromatography", Human Gene Therapy Methods, (20120201), vol. 23, no. 1, doi:10.1089/hgtb.2011.217, ISSN 1946-6536, pages 56 - 64, XP055349796
OPPOSITION- Darby L. Thomas, Lijun Wang, Justine Niamke, Jilin Liu, Wen Kang, Marina M. Scotti, Guo-Jie Ye, Gabor Veres, David R. Knop, "Scalable Recombinant Adeno-Associated Virus Production Using Recombinant Herpes Simplex Virus Type 1 Coinfection of Suspension-Adapted Mammalian Cells", Human Gene Therapy, Mary Ann Liebert, (20090801), vol. 20, no. 8, doi:10.1089/hum.2009.004, ISSN 10430342, pages 861 - 870, XP055043924
OPPOSITION- VIRAG, T. et al., "Producing recombinant adeno-associated virus in foster cells: overcoming production limitations using a baculovirus-insect cell expression strategy", Human Gene Therapy, (20090800), vol. 28, no. 8, doi:10.1089/hum.2009.092, pages 807 - 817, XP055052744
OPPOSITION- VIRAG T. et al., "Producing Recombinant Adeno-Associated Virus in Foster Cells: Overcoming Production Limitations Using a Baculovirus-lnsect Cell Expression Strategy", HUMAN GENE THERAPY, (20090800), vol. 20, doi:10.1089/hum.2009.092, pages 807 - 817, XP055052744
OPPOSITION- CLEMENT, N . et al., "Large-Scale Adeno-Associated Viral Vector Production Using a Herpesvirus-Based System Enables Manufacturing for Clinical Studies", Human Gene Therapy, (20090801), vol. 20, no. 8, pages 769 - 806, XP055041035
OPPOSITION- CHULAY, J. D. et al., "Preclinical evaluation of a recombinant adeno-associated virus vector expressing human alpha-1 antitrypsin made using a recombinant herpes simplex virus production method", Human Gene Therapy, (20110200), vol. 22, no. 2, pages 155 - 165, XP055841157
OPPOSITION- CHULAY, J. D. et al., "Preclinical Evaluation o f a Recombinant Adeno-Associated Virus Vector Expressing Human Alpha-1 Antitrypsin Made Using a Recombinant Herpes Simplex Virus Production Method", Human Gene Therapy, (20110200), vol. 22, no. 2, pages 155 - 165, XP055841157
OPPOSITION- ALLAY, J. A. et al., "Good Manufacturing Practice Production of Self-Complementary Serotype 8 Adeno-Associated Viral Vector for a Hemophilia B Clinical Trial", Human Gene Therapy, (20110000), doi:10.1089/hum.2010.202, pages 595 - 604, XP055349809
OPPOSITION- FLOTTE, T. R. et al., "Phase 2 Clinical Trial of a Recombinant Adeno-Associated Viral Vector Expressing alphal-Antitrypsin: Interim Results", Human Gene Therapy, (20111000), vol. 22, no. 10, pages 1239 - 1247, XP055841159
OPPOSITION- MIETZSCH et al., "OneBac: Platform for Scalable and High-Titer Production of Adeno- Associated Virus Serotype 1-12 Vectors for Gene Therapy", HUMAN GENE THERAPY, (20140300), vol. 25, doi:10.1089/hum.2013.184, pages 212 - 222, XP055416407
OPPOSITION- NEGRETE, A. et al., "Strategies for manufacturing recombinant adeno-associated virus vectors for gene therapy applications exploiting baculovirus technology", Briefings in Functional Genomics and Proteomics, (20080700), vol. 7, no. 4, doi:10.1093/bfgp/eln034, pages 303 - 311, XP055454105
OPPOSITION- KOTIN, R. M., "Large-scale recombinant adeno-associated virus production", Human Molecular Genetics, (20110400), vol. 20, no. R1, doi:10.1093/hmg/ddr141, pages R2 - R6, XP055016870
OPPOSITION- QU W. et al., "Scalable Downstream Strategies for Purification of Recombinant Adeno-Associated Virus Vectors in Light of the Properties", Current Pharmaceutical Biotechnology, (20150000), vol. 16, doi:10.2174/1389201016666150505122228, pages 684 - 695, XP055533837
OPPOSITION- QU, W. et al., "Scalable downstream strategies for purification of recombinant adeno- associated virus vectors in light of the properties", Current Pharmaceutical Biotechnology, (20150800), vol. 16, no. 8, doi:10.2174/1389201016666150505122228, pages 684 - 695, XP055533837
OPPOSITION- AYUSO, E. et al., "Production, purification and characterization of adeno-associated vectors", Current Gene Therapy, (20101200), vol. 10, no. 6, doi:10.2174/156652310793797685, pages 423 - 436, XP009516742
OPPOSITION- MERTEN et al., "Manufacturing of viral vectors: part II. Downstream processing and safety aspect s", Pharm. Bioprocess., (20140000), vol. 2, no. 3, doi:10.4155/pbp.14.15, pages 237 - 251, XP055615575
OPPOSITION- MERTEN, O. W. et al., "Manufacturing of viral vectors: Part II. Downstream processing and safety aspects", Pharmaceutical Bioprocessing, (20140000), vol. 2, no. 3, doi:10.4155/pbp.14.15, pages 237 - 251, XP055615575
OPPOSITION- MERTEN O-W. et al., "Manufacturing of viral vectors: part II. Downstream processing and safety aspects", Pharm. Bioprocess., (20140000), vol. 2, no. 3, doi:10.4155/pbp.14.15, pages 237 - 251, XP055615575
OPPOSITION- Otto-Wilhelm Merten, Matthias Schweizer, Parminder Chahal, Amine Kamen, "Manufacturing of viral vectors: part II. Downstream processing and safety aspects", Pharmaceutical Bioprocessing, (20140601), vol. 2, no. 3, doi:10.4155/pbp.14.15, ISSN 2048-9145, pages 237 - 251, XP055615575

Download Citation Report

Get a free citation report including examiner, opposition, and international search citations.

Get Citation Report

Dossier Documents

The dossier documents provide a comprehensive record of the patent’s prosecution history - including filings, correspondence, and decisions made by patent offices - and are crucial for understanding the patent’s legal journey and any challenges it may have faced during examination.

  • Date

    Description

  • Get instant alerts for new documents